G2GBIO Inc. (KOSDAQ:456160)

South Korea flag South Korea · Delayed Price · Currency is KRW
79,000
-2,800 (-3.42%)
At close: Apr 28, 2026
Market Cap 1.31T
Revenue n/a
Net Income n/a
Shares Out 16.55M
EPS n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 208,811
Average Volume 262,090
Open 79,800
Previous Close 81,800
Day's Range 77,300 - 81,000
52-Week Range 27,567 - 124,000
Beta n/a
RSI 51.99
Earnings Date n/a

About G2GBIO

G2GBIO Inc., a clinical-stage biotech company, provides pharmaceutical products. The company’s pipeline products include GB-5001, GB-5001A, and GB-5112 for the treatment of Alzheimer’s disease; GB-6002, an opioid drug that is used for post-operative pain treatment; GB-7001 for type-2 diabetes treatments; GB-5313 for the treatment of Osteoarthritis; GB-7101 and GB-7103 for the treatment of prostate cancer; GB-6201 and GB-6203 for androgenetic alopecia treatments; and GH-001 for the treatment of Hepatitis B. It also develops GB-2001 for animal ca... [Read more]

Industry Pharmaceutical Preparations
Founded 2017
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 456160
Full Company Profile

News

There is no news available yet.